Astellas, Gilead Sue Amphastar to Block Copies of Lexiscan Drug

Feb. 25, 2020, 10:57 PM

Astellas and Gilead said proposed copies of the drug, used to help detect heart disease, by Amphastar’s International Medication Systems unit infringe three patents for Lexiscan.

  • Astellas and Gilead are seeking a court order blocking copies until the patents have expired, and to collect cash compensation if copies are made before then, according to a complaint filed Tuesday in federal court in Wilmington, Delaware
  • Lexiscan, injected before an imaging test that shows how well blood flows through the heart, helps doctors detect coronary artery disease
  • Gilead owns the patents and licenses them exclusively to Astellas, according to the complaint ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.